Ehrlich, Marc
Hentschke, Christian
Sieder, Christian
Maier-Peuschel, Monika
Reuter, Uwe
Funding for this research was provided by:
Novartis Pharma GmbH, Nuremberg, Germany
Article History
Received: 13 September 2022
Accepted: 19 October 2022
First Online: 15 November 2022
Declarations
:
: The study protocol, protocol amendments, informed consent forms, and accompanying materials were reviewed and approved by the Institutional Review Board /Independent Ethics Committee and Health Authorities at each study center.All participants provided written informed consent before undergoing any study-specific procedures.
: Consent for publication was received.
: Uwe Reuter reports grants, personal fees and other from Novartis, and personal fees and other from Amgen during the conduct of the study. He reports personal fees and other from AbbVie; grants, personal fees and other from Allergan; other from Alder; personal fees and other from Eli Lilly; personal fees from Lundbeck; personal fees from Pfizer; personal fees from Medscape and StreaMedUP; grants, personal fees and other from Novartis; and personal fees from Teva Pharmaceuticals outside the submitted work.Marc Ehrlich, Monika Maier-Peuschel, Christian Sieder, and Christian Hentschke are employees of, and hold stocks in Novartis.